HYGIEIA. REFORMING INSULIN THERAPY AS WE KNOW IT.

We are Hygieia. And we are singularly focused on revolutionizing how people manage their insulin. Using science, research and technology, we developed a breakthrough and highly effective insulin management program that not only changes how patients and physicians manage insulin today, but also establishes the standard of autonomous insulin dose adjustment.

With over seven million Americans with type 2 diabetes using insulin and only 33% achieving successful results, the need for a monumental shift in insulin management has never been greater. Hygieia’s founders, Dr. Eran Bashan and Dr. Israel Hodish answer the call with d-Nav Technology² — an FDA-cleared breakthrough insulin management tool designed to significantly improve and simplify insulin treatment so that more people who are on insulin therapy succeed.

From inception, it has been our mission to redefine the way the world manages insulin, and we are committed to leading the charge.

MANAGEMENT TEAM

Eran Bashan, PhD

CEO & Chairman of the Board

About Eran

Eran Bashan has over 20 years experience in leadership, execution, research, innovation, and team building. He co-founded Hygieia in 2008 and demonstrated his ability to bring products from ideation to commercialization. Prior to Hygieia, Eran managed R&D at OTM Technologies, a startup company focusing on unique optical sensor applications. Prior to OTM, Eran was with Elbit Systems (NASDAQ:ESLT). He also spent several years as a lecturer. Eran started his career in the military as a field officer where he was a Company Commander in the Armor Corps. Eran holds a PhD in Electrical Engineering Systems from the University of Michigan.

Israel Hodish, MD, PhD

Co-founder & Medical Director

About Dr. Hodish

Mark Willis

Chief Technology Officer

About Mark

Mark Willis is an experienced lead architect who actively partners with executive leadership to understand their vision and the direction for the business. During the last 30 years, Mark co-founded three technology companies, the most recent in healthcare. As Chief Architect, he guided one of these companies to become a fully-operational, worldwide presence with state-of-the-art infrastructure and custom line-of-business applications connecting offices on five continents. He successfully creates a blueprint for utilizing technology to fully realize business objectives, enabling his teams to tailor solutions that support evolution of the business strategy. Mark’s hands-on leadership positions his team to facilitate Hygieia’s vision for worldwide commercialization of its products and services.

Donna McCollum

Vice President of Research & Development

About Donna

Donna McCollum is Vice President of Research and Development for Hygieia, Inc.. She is responsible for leading the product development efforts, product support, and quality system and regulatory compliance.

Donna has spent 30 years in medical device product development and quality systems, and has been with Hygieia since 2010, supporting d-Nav product development and certification efforts.

Prior to Hygieia, Donna served in various quality system and product development roles at Terumo Cardiovascular including Product Development Technical Manager and project lead for System 1, the next generation heart lung machine.

Donna has a BS degree in Biomedical Engineering from the University of Tennessee and holds MS and PhD degrees in Biomedical Engineering from Duke University.

Steve Calef

Vice President of Finance

About Steve

Steve Calef leads Hygieia’s accounting, treasury and risk management functions, as well as partners with leadership in achieving the company’s strategic goals. Steve brings extensive experience in financial and operational management with organizations in several industries at various stages. His track record includes fundraising at the angel and venture capital levels, as well as a successful exit to private equity. Operationally, Steve has been a part of several ERP implementations and has led purchasing and inventory management to meet the needs of changing markets. Prior to joining Hygieia, he held CFO/VP of Finance roles at Great Lakes Ace Hardware, Epsilon Imaging and Enovate Medical. Steve holds an MBA in Finance from Mercer University.

Zoe Heineman

Vice President of Business Development

About Zoe

Zoe Heineman has 30 years of expertise in strategic leadership, operations, and business development in biopharmaceuticals and medical devices. While attending graduate school, she was diagnosed with type 1 diabetes inspiring her focus on improving access to care.

She led the coalition responsible for adding coverage of insulin pump therapy and disposable supplies to Medicare, was a start-up team member at Disetronic, an insulin delivery device manufacturer later acquired by Roche for $1.3 billion, a co-chair of the American Association of Clinical Endocrinology Corporate Advisory Board, and a board member of the Lawson Wilkins Pediatric Endocrinology Society.

Zoe has an MS in Education from Johns Hopkins and an Executive MBA in Pharmaceutical Marketing from Rutgers.

Gilad Lederer

Head of International Business Development

About Gilad

Gilad is an experienced entrepreneur with a demonstrated history of working across many disciplines within the tech industry. With a strong track record of business development in multiple countries across the globe, he brings to Hygiea his skills in business planning, entrepreneurship, strategic partnerships, and execution of large deals in the USA, Europe, Africa, China and Japan. Gilad represents Hygieia’s interest in licensing opportunities outside of the USA.

BOARD OF DIRECTORS

John Brooks

Board Member

About John

John L. Brooks III is the Managing Director of Healthcare Capital LLC, a consulting firm that is enabling innovative solutions in obesity, pre-diabetes, and diabetes pandemics. John is the former President and Chief Executive Officer of the Joslin Diabetes Center, a Boston based diabetes research, clinical care, and education organization. A well-known life sciences executive, Mr. Brooks has co-founded seven life sciences companies, including Insulet (PODD), a disruptive insulin delivery company. He was a co-founder of Prism Venture Partners, a $1.25B venture capital firm. Prior to that, John was the Emerging Business Group General Manager at Pfizer/Valleylab, where he was responsible for Pfizer’s minimally invasive surgery and new medical technologies businesses. As President/GM at Pfizer/Strato, he led the growth of a rapidly evolving vascular access medical device business. A native of Massachusetts, he holds an M.S. in Business Administration and a B.B.A. cum laude from the University of Massachusetts at Amherst and he is a Certified Public Accountant. Mr. Brooks is on the board of a number of for-profit and not-for-profit organizations.

Mark Hirschhorn

Board Member

About Mark

Mark Hirschhorn is currently the CEO of Tapestry Health, a multi-specialty physician practice providing clinical services for patients in skilled nursing facilities and assisted living facilities.

Mark is a recognized innovator in the digital healthcare industry where he has held several leadership roles in top virtual-care companies. He was president, COO and CFO of Talkspace; COO and CFO of Teladoc; and CFO of ArisGlobal. While at Teladoc Health, the nation’s leading provider of telehealth services, Mark grew the company from 45 to 2,500 employees, and from $10M in sales to $500 million. He has previously held senior executive positions at several other technology companies, including RCS/Media Monitors and BT Radianz.

Charles Bisgaier

Board Member

About Charles

Charles Bisgaier co-founded and is Chief Executive Manager of Michigan Life Ventures (MLV) and Michigan Life Therapeutics (MLT). Previously, he was President/CEO at ProNAi Therapeutics, a cancer therapeutic company. Charles also co-founded and was VP of Pharmacology at Esperion Therapeutics (acquired by Pfizer). Prior to Esperion, Charles participated in the discovery and development of Gemfibrozil (Lopid®), Atorvastatin (Lipitor®), Avasimibe and Gemcabene at Warner-Lambert/Parke-Davis. Currently, he licensed Gemcabene from Pfizer and is in clinical development at Gemphire Therapeutics Inc. Through MLV he invests in innovative early stage/start-up companies. Charles received his Biochemistry Ph.D. (1981) from George Washington University.

Nir Tarlovsky

Board Member

About Nir

Nir Tarlovsky has been an entrepreneur and angel investor for the last 30 years. He is the co-founder and managing partner of Firstime Ventures, a venture capital fund, investing in Pre A & A rounds , focused on cutting edge, disruptive technologies, based on state of the art ideas and headed by brilliant people. Nir is also the executive chairman of Pixellot, and is skilled in e-commerce, entrepreneurship, venture capital, strategic partnerships, and mobile applications. Throughout his career, Nir has sat on numerus boards and has been involved with multiple M&S and IPOs.

ADVISORY BOARD

Richard M. Bergenstal, MD

About Dr. Bergenstal

Dr. Bergenstal is an endocrinologist and Executive Director of the International Diabetes Center at Park Nicollet. He is Clinical Professor at the University of Minnesota and in 2010 was the American Diabetes Association’s, President, Medicine & Science. In 2007, he was ADA’s Outstanding Physician Clinician. He currently serves as IDC’s principal investigator for three NIH trials: the DCCT/EDIC (T1D) and the ACCORD follow-up and GRADE studies (T2D). He works to implement patient-centered team care utilizing new technology for glucose analysis and management.

George Grunberger, MD

About Dr. Grunberger

Dr. Grunberger is Chairman of the Grunberger Diabetes Institute (GDI) in Bloomfield Hills, Michigan. Dr. Grunberger serves as a Clinical Professor of Internal Medicine at Wayne State University School of Medicine in Detroit, Michigan, and Professor of Internal Medicine at Oakland University William Beaumont School of Medicine in Auburn Hills, Michigan. A Fellow of the American College of Physicians and American College of Endocrinology, Dr. Grunberger has authored more than 150 scientific articles in peer-reviewed journals and served as an investigator of more than 100 clinical research studies and trials. He is a Past President of the American Association of Clinical Endocrinologists (AACE) and served on the AACE National Board of Directors from 2006 to 2012. In addition, he is the Past President of the Michigan Chapter of the AACE.

Mark Fendrick, MD

About Dr. Fendrick

Dr. Fendrick is a Professor of Internal Medicine in the School of Medicine and Professor of Health Management and Policy in the School of Public Health at the University of Michigan. He currently directs the V-BID Center at the University of Michigan. His research focuses on how clinician payment and consumer engagement initiatives impact access to care, quality of care, and health care costs. Dr. Fendrick has authored over 250 articles and book chapters and has received numerous awards. Dr. Fendrick is an elected member of the National Academy of Medicine (formerly IOM) and serves on the Medicare Coverage Advisory Committee. He is the co-editor in chief of the American Journal of Managed Care and is an editorial board member for 3 additional peer-reviewed publications. He is also a member of the Institute for Healthcare Policy and Innovation at the University of Michigan.

Michael J. Miller, MD

About Dr. Miller

Dr. Miller is a former Medical Director of the MidMichigan Medical Center, Diabetes Center in Midland where he practiced for 35 years. Board Certified in Diabetes and Endocrinology and Internal Medicine, his clinical practice focused on advanced diabetes management. Recognized as one of the first diabetes practitioners granted Certified Diabetes Technology Clinician (CDTC) status, Dr. Miller is also a lifetime member of the ADA and AACE, and a Fellow of the American College of Clinical Endocrinology (AACE). Dr. Miller co-founded LifeScan Inc. and served on its Board prior to Johnson & Johnson’s 1986 acquisition. He was recently named Clinical Advisor to Thermalin Diabetes LLC (Cleveland, OH).

Karen Drexler

About Karen

Karen Drexler is a serial entrepreneur with expertise in the fields of digital health, medical devices and diagnostics. Currently, she serves on the boards of ResMed; VIDA Diagnostics; Outset Medical; Bone Health Technologies; Tivic Health; and EBR Systems. Karen is also an active mentor and advisor with Astia, and a lead mentor with StartX, the Stanford University incubator. Previously, Karen was the CEO of Sandstone Diagnostics, served as the board chair of Hygieia, and spent 11 years on the board of the Keller Center for Innovation in Engineering Education at Princeton University. Earlier in her career, Karen was founder and CEO of Amira Medical (acquired by Roche in 2001), held management roles at LifeScan and played a key role in its sale to J&J.

NEWS

Discover important news about d-Nav and type 2 diabetes.

Learn more

CONTACT

Let us know if
we can help.

HYGIEIA. REFORMING INSULIN THERAPY AS WE KNOW IT.

MANAGEMENT TEAM

BOARD OF DIRECTORS

ADVISORY BOARD

NEWS

CONTACT

SUBSCRIBE TO OUR NEWSLETTER

FOLLOW US ON SOCIAL